The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism
Section snippets
Materials
The DNA sequencing and mutagenic oligonucleotide primers were synthesized at the Molecular Genetics Instrumentation Facility, University of Georgia, Athens, GA. Primers for the construction of the expression construct were synthesized by Bethesda Research Laboratories (Gaithersburg, MD). Restriction endonucleases, the GeneEditor in vitro site-directed mutagenesis system, R408 helper phage, E. coli DH5α competent cells, and plasmid preparation kit were obtained from Promega (Madison, WI).
Expression and purification of P450 1A1 and 1A2 WT and mutant enzymes
The choice of P450 1A1 and 1A2 residues subjected to mutagenesis was based on the analysis of enzyme–substrate interactions in the active site of the P450 1A1 homology model and the sequence alignment between 1A1 and 1A2. Among several key active site residues identified [10], only five were different between P450 1A1 and 1A2. The positions of these residues in a linear sequence are shown in Fig. 2A. In P450 1A1, the unique active site residues are thus Ser-122, Asn-221, Gly-225, Leu-312, and
Discussion
The overall objective of this study was to evaluate sites suggested by the predictions from homology modeling and substrate docking, and to alter substrate specificity of the P450 1A enzymes by single reciprocal mutations. Additionally, we examined the utility of molecular modeling to provide rationale for substrate specificity in terms of substrate dynamics in the active site. In our previous work [10], we have shown that binding free energy calculations in homology models can be successfully
Acknowledgements
This work was supported by NIH Grants CA85542 and RR16440 (G.D.S.) and by ES07628 (C.W.F.). Modeling studies were performed at the Computational Chemistry and Molecular Modeling Laboratory, Department of Basic Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV.
References (33)
- et al.
Biochem. Pharmacol.
(1993) - et al.
Arch. Biochem. Biophys.
(1996) - et al.
Arch. Biochem. Biophys.
(1996) - et al.
Biochem. Biophys. Acta
(1993) - et al.
J. Biol. Chem.
(1991) - et al.
J. Biol. Chem.
(1951) - et al.
Biochem. Pharmacol.
(1994) - et al.
Biochim. Biophys. Acta
(1999) J. Biol. Chem.
(1992)- et al.
Biochem. Biophys. Res. Commun.
(1998)
Drug Metab. Rev.
Biochemistry
Carcinogenesis
Chem. Res. Toxicol.
Cited by (64)
Novel cytochrome P450 1 (CYP1) genes in tree shrews are expressed and encode functional drug-metabolizing enzymes
2023, Comparative Biochemistry and Physiology Part - C: Toxicology and PharmacologyLC-MS-based assay of granisetron 7-hydroxylation activity for the evaluation of CYP1A1 induction from diesel particulate matter-exposed hepatic and respiratory cell lines
2022, Food and Chemical ToxicologyCitation Excerpt :Thus, granisetron 7-hydroxylation showed a meaningful correlation and inducibilities in hepatic and extrahepatic cells. The resorufin-based assays, including EROD and 7-methoxyresorufin O-demethylation (MROD), are widely used measurements of CYP1A1 and CYP1A2 activities (Burke et al., 1994; Liu et al., 2004). In the MROD assay, MROD has also overlapped the contribution of CYP1A1 and CYP1A2 with similar efficacy (Kapelyukh et al., 2019).
Phe-125 and Phe-226 of pig cytochrome P450 1A2 stabilize the binding of aflatoxin B<inf>1</inf> and 7-ethoxyresorufin through the key CH/π interactions
2019, Biochemical PharmacologyCitation Excerpt :Therefore, it is possible to omit some key sites related to the substrate catalysis. For example, Leu-382 is reported to be important residue for the EROD activity in other researches [24,48]. This issue should be improved by more precise prediction.
Molecular adaptation to high pressure in cytochrome P450 1A and aryl hydrocarbon receptor systems of the deep-sea fish Coryphaenoides armatus
2018, Biochimica et Biophysica Acta - Proteins and ProteomicsCharacterization of cytochrome P450 CYP109E1 from Bacillus megaterium as a novel vitamin D<inf>3</inf> hydroxylase
2017, Journal of Biotechnology
- 1
Present address: CEDRA Corporation, 8609 Cross Park Drive, Austin, TX 78754, USA.